Payment overview · 2025
General Payments
$357.75
38 reported records · 9 companies
Healthcare provider profile · identity verified
Lee B Taylor, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPARTANBURG, SC · NPI 1003863929
Verified facts
What the public records show
CMS Open Payments records show Lee B Taylor, MD received $357.75 in general payments during 2025 across 38 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.17 | 38.1% | 26 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $79.77 | 22.3% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $31.68 | 8.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.03 | 6.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.25 | 6.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.22 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.51 | 4.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $14.17 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.95 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.75 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $136.17 | 26 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $79.77 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 252 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 307 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
252 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
307 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
127 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
252 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1420 | 390 |
| Pioglitazone Hcl | Pioglitazone Hcl | 705 | 189 |
| Prednisone | Prednisone | 629 | 355 |
| Famotidine | Famotidine | 607 | 240 |
| Atorvastatin Calcium | Atorvastatin Calcium | 562 | 140 |
| Omeprazole | Omeprazole | 552 | 168 |
| Losartan Potassium | Losartan Potassium | 499 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 110 |
| Farxiga | Dapagliflozin Propanediol | 394 | 64 |
| Azithromycin | Azithromycin | 382 | 285 |
| Escitalopram Oxalate | Escitalopram Oxalate | 312 | 89 |
| Ozempic | Semaglutide | 307 | 59 |
| Carvedilol | Carvedilol | 297 | 75 |
| Ramipril | Ramipril | 288 | 80 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 278 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 74 |
| Ezetimibe | Ezetimibe | 263 | 75 |
| Eliquis | Apixaban | 252 | 47 |
| Gabapentin | Gabapentin | 247 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 69 |
| Metformin Hcl | Metformin Hcl | 224 | 62 |
| Potassium Chloride | Potassium Chloride | 217 | 62 |
| Lorazepam | Lorazepam | 207 | 45 |
| Mounjaro | Tirzepatide | 191 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 57 |
| Trazodone Hcl | Trazodone Hcl | 171 | 53 |
| Clonazepam | Clonazepam | 167 | 23 |
| Montelukast Sodium | Montelukast Sodium | 164 | 51 |
| Temazepam | Temazepam | 147 | 21 |
| Allopurinol | Allopurinol | 144 | 40 |
| Xarelto | Rivaroxaban | 130 | 22 |
| Rybelsus | Semaglutide | 127 | 20 |
| Jardiance | Empagliflozin | 119 | 30 |
| Simvastatin | Simvastatin | 117 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 31 |
| Memantine Hcl | Memantine Hcl | 109 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 52 |
| Januvia | Sitagliptin Phosphate | 104 | 17 |
| Furosemide | Furosemide | 103 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 28 |
| Lisinopril | Lisinopril | 97 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 27 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 94 | 74 |
| Meloxicam | Meloxicam | 93 | 35 |
| Sertraline Hcl | Sertraline Hcl | 90 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 71 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 88 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 52 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 84 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 25 |
| Bupropion Xl | Bupropion Hcl | 79 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 19 |
| Celecoxib | Celecoxib | 75 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 75 | 64 |
| Warfarin Sodium | Warfarin Sodium | 75 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 20 |
| Pitavastatin Calcium | Pitavastatin Calcium | 69 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 52 |
| Glyxambi | Empagliflozin/Linagliptin | 67 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 66 | 22 |
| Finasteride | Finasteride | 66 | 20 |
| Repatha Sureclick | Evolocumab | 65 | 14 |
| Chlorthalidone | Chlorthalidone | 63 | 19 |
| Fluconazole | Fluconazole | 63 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 37 |
| Tramadol Hcl | Tramadol Hcl | 62 | 17 |
| Synthroid | Levothyroxine Sodium | 61 | 16 |
| Levofloxacin | Levofloxacin | 59 | 44 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 17 |
| Meclizine Hcl | Meclizine Hcl | 57 | 34 |
| Spironolactone | Spironolactone | 57 | 20 |
| Trulicity | Dulaglutide | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 12 |
| Valacyclovir | Valacyclovir Hcl | 52 | 32 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Lansoprazole | Lansoprazole | 50 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 15 |
| Tradjenta | Linagliptin | 45 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Valsartan | Valsartan | 41 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 40 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Estradiol | Estradiol | 37 | 20 |
| Nexletol | Bempedoic Acid | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Praluent Pen | Alirocumab | 35 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 34 | 17 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Ketoconazole | Ketoconazole | 34 | 19 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Carisoprodol | Carisoprodol | 32 | 25 |
| Dutasteride | Dutasteride | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 25 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 19 |
| Amoxicillin | Amoxicillin | 23 | 13 |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Colchicine | Colchicine | 20 | suppressed |
| Edarbi | Azilsartan Medoxomil | 20 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 19 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Steglujan | Ertugliflozin/Sitagliptin Phos | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.75 · 38 records | Bayer Healthcare Pharmaceuticals Inc. | Azstarys, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, KRYSTEXXA, Kerendia, NURTEC ODT, Ozempic, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error